Literature DB >> 23335116

Factors associated with poor quality of life in survivors of childhood acute lymphoblastic leukemia and lymphoma.

Adriani Kanellopoulos1, Hanne Mari Hamre, Alv A Dahl, Sophie D Fosså, Ellen Ruud.   

Abstract

BACKGROUND: Previous studies of health-related quality of life (QoL) in childhood cancer survivors have hardly focused on factors associated with poor QoL. THE AIMS OF OUR STUDY WERE: (1) to assess QoL in long-term survivors (LTSs) of childhood acute lymphoblastic leukemia (ALL) and lymphomas compared to age-matched controls from the general population (NORMs). (2) To investigate factors associated with poor QoL in LTSs. PROCEDURE: This population-based cross-sectional study enrolled 285 LTSs of ALL and lymphomas diagnosed between 1970 and 2002 at age <18 years. The LTSs completed an extensive mailed questionnaire including the Short Form 36 (SF-36) as QoL-measure. NORMs consisted of five age-matched controls for each LTS (N = 1,425). Poor QoL was defined as SF-36 physical or mental component summary score <40.
RESULTS: The median age of LTSs' at survey was 30 years (range: 18-54), median follow-up time 21 years (range: 7-39). Compared to NORMs, LTSs scored significantly lower on 7 of 8 SF-36 subscales. Among LTSs 32% reported poor QoL versus 19% among NORMs (P < 0.001). Among LTSs, psychosocial, lifestyle- and health-related variables, but not type of malignancy, treatment factors or socio-demographic factors were clinically significantly associated with poor QoL in bivariate regression analyses. In multivariate analysis, levels of fatigue, anxiety and depression, as well as obesity and insomnia remained significantly associated with poor QoL.
CONCLUSION: Significantly more LTSs than age-matched NORMs experienced poor QoL. Clinically significant associations with fatigue, anxiety, depression, obesity and insomnia were observed, which may be amenable for interventions, and thereby improvement of QoL in LTSs.
Copyright © 2013 Wiley Periodicals, Inc.

Entities:  

Mesh:

Year:  2013        PMID: 23335116     DOI: 10.1002/pbc.24375

Source DB:  PubMed          Journal:  Pediatr Blood Cancer        ISSN: 1545-5009            Impact factor:   3.167


  28 in total

1.  Dental abnormalities after chemotherapy in long-term survivors of childhood acute lymphoblastic leukemia 7-40 years after diagnosis.

Authors:  Petter Wilberg; Adriani Kanellopoulos; Ellen Ruud; Marianne Jensen Hjermstad; Sophie Dorothea Fosså; Bente Brokstad Herlofson
Journal:  Support Care Cancer       Date:  2015-09-12       Impact factor: 3.603

2.  Psychosocial Outcomes of Sharing a Diagnosis of Cancer with a Pediatric Patient.

Authors:  Haya Raz; Nili Tabak; Shulamith Kreitler
Journal:  Front Pediatr       Date:  2016-07-20       Impact factor: 3.418

3.  Weight change during childhood acute lymphoblastic leukemia induction therapy predicts obesity: a report from the Children's Oncology Group.

Authors:  Janice S Withycombe; Lynette M Smith; Jane L Meza; Carrie Merkle; Melissa Spezia Faulkner; Leslie Ritter; Nita L Seibel; Ki Moore
Journal:  Pediatr Blood Cancer       Date:  2014-11-18       Impact factor: 3.167

4.  Peripheral Neuropathy, Sensory Processing, and Balance in Survivors of Acute Lymphoblastic Leukemia.

Authors:  Mitra Varedi; Lu Lu; Carrie R Howell; Robyn E Partin; Melissa M Hudson; Ching-Hon Pui; Kevin R Krull; Leslie L Robison; Kirsten K Ness; Raymond F McKenna
Journal:  J Clin Oncol       Date:  2018-05-29       Impact factor: 44.544

5.  Educational attainment among long-term survivors of cancer in childhood and adolescence: a Norwegian population-based cohort study.

Authors:  Sara Ghaderi; Anders Engeland; Maria Winther Gunnes; Dag Moster; Ellen Ruud; Astri Syse; Finn Wesenberg; Tone Bjørge
Journal:  J Cancer Surviv       Date:  2015-05-01       Impact factor: 4.442

6.  Relationship between sleep problems and psychological outcomes in adolescent and young adult cancer survivors and controls.

Authors:  Lauren Daniel; Anne E Kazak; Yimei Li; Wendy Hobbie; Jill Ginsberg; Eliana Butler; Lisa Schwartz
Journal:  Support Care Cancer       Date:  2015-07-01       Impact factor: 3.603

Review 7.  Neurocognitive Dysfunction in Hematopoietic Cell Transplant Recipients: Expert Review from the Late Effects and Quality of Life Working Committee of the Center for International Blood and Marrow Transplant Research and Complications and Quality of Life Working Party of the European Society for Blood and Marrow Transplantation.

Authors:  Debra Lynch Kelly; David Buchbinder; Rafael F Duarte; Jeffrey J Auletta; Neel Bhatt; Michael Byrne; Zachariah DeFilipp; Melissa Gabriel; Anuj Mahindra; Maxim Norkin; Helene Schoemans; Ami J Shah; Ibrahim Ahmed; Yoshiko Atsuta; Grzegorz W Basak; Sara Beattie; Sita Bhella; Christopher Bredeson; Nancy Bunin; Jignesh Dalal; Andrew Daly; James Gajewski; Robert Peter Gale; John Galvin; Mehdi Hamadani; Robert J Hayashi; Kehinde Adekola; Jason Law; Catherine J Lee; Jane Liesveld; Adriana K Malone; Arnon Nagler; Seema Naik; Taiga Nishihori; Susan K Parsons; Angela Scherwath; Hannah-Lise Schofield; Robert Soiffer; Jeff Szer; Ida Twist; Anne Warwick; Baldeep M Wirk; Jean Yi; Minoo Battiwalla; Mary E Flowers; Bipin Savani; Bronwen E Shaw
Journal:  Biol Blood Marrow Transplant       Date:  2017-09-20       Impact factor: 5.742

8.  Health-Related Quality of Life among Children and Adolescents during Hematopoietic Stem Cell Transplant Recovery.

Authors:  Cheryl Rodgers; Patricia Wills-Bagnato; Richard Sloane; Marilyn Hockenberry
Journal:  J Pediatr Oncol Nurs       Date:  2015-01-15       Impact factor: 1.636

Review 9.  Development of depression in survivors of childhood and adolescent cancer: a multi-level life course conceptual framework.

Authors:  Erica C Kaye; Tara M Brinkman; Justin N Baker
Journal:  Support Care Cancer       Date:  2017-03-09       Impact factor: 3.603

10.  Fatigue in adolescent and adult survivors of non-CNS childhood cancer: a report from project REACH.

Authors:  Natasha N Frederick; Lisa Kenney; Lynda Vrooman; Christopher J Recklitis
Journal:  Support Care Cancer       Date:  2016-04-27       Impact factor: 3.603

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.